Invivyd Loss Submission Form

Company: Invivyd, Inc. f/k/a Adagio Therapeutics, Inc.

Ticker: (NASDAQ) IVVD

Deadline

Passed

Lead Plaintiff Deadline: April 03, 2023

Case Alerts

Every year, thousands of shareholders miss deadlines to receive settlement funds. Make sure you don’t. Sign up for case alerts.

To receive more detailed alerts provide your information below.

Request Case Alerts

Levi & Korsinsky, LLP does not share your information with others. There is no cost or obligation for you to submit. No spam will be sent to your email.

Allegations

The filed complaint alleges that Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that:

(a) the published epitope mapping, structural studies, and sequence analyses which defendants had used to claim that ADG20, an investigational monoclonal antibody treatment for COVID-19, was effective against Omicron were insufficient, unreliable, and inadequate to make claims of effectiveness of ADG20 against Omicron; (b) defendants’ claims regarding ADG20’s efficacy against Omicron lacked a reasonable factual basis; and (c) ADG20 was over 300 times less effective against the Omicron variant as compared to its effectiveness against previous variants.